Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

Merger report boosts Ariad stock

By , Globe Staff

Discussions with the developer of leukemia and lung-cancer treatments continue and there is no certainty a deal will be reached.

FDA approves Marlborough company’s epilepsy drug

By , Globe Staff

An epilepsy tablet made by Sunovion Pharmaceuticals won US approval Friday to be sold as a primary therapy.

FDA approves new Amgen cholesterol drug

By , Globe Staff

The drug can reduce levels of bad cholesterol in millions of people who don’t respond to or are only partly helped by statins.

PureTech’s long view on biopharma

By , Globe Staff

Having hatched a dozen companies, PureTech is betting big with a hybrid model more common across the Atlantic.